Devendra Wadwekar, MD
Endocrinology, Diabetes & Metabolism · Gilbert, AZNPI 1174504534
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 18.6%. Reporting peaked in 2019 at $11,264 and has fallen 59.6% since, to $4,551 in 2025. Among endocrinology, diabetes & metabolism clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 858 payments — averaging $45.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$7K
- Madrigal Pharmaceuticals$7K
- Lilly USA, LLC$6K
- Mannkind Corporation$6K
- Insulet Corporation$2K
- Medtronic$1K
- plus $10K from 54 others
What the payments were for
- Consulting fees$5,97515%
- Speaking & faculty fees$10,86328%
- Travel & lodging$5,38014%
- Food & beverage$16,51942%
- Education$640%
- Gifts$590%
- Entertainment$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$10,922
- REZDIFFRA$6,547
- AFREZZA$5,271
- Korlym$404
- Omnipod$277
- MINIMED 780G$274
- FibroScan$198
- Minimed 670G System$184
- Minimed 530G$119
- CeQur Simplicity$100
How this compares
$38,875 in reported general payments places this provider in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 382 | $612,214 |
| MounjaroTirzepatide | 364 | $549,967 |
| JardianceEmpagliflozin | 151 | $188,399 |
| TrulicityDulaglutide | 110 | $179,216 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 94 | $131,075 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $75,138 |
| FarxigaDapagliflozin Propanediol | 76 | $69,795 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $61,346 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $56,003 |
| RezdiffraResmetirom | 13 | $52,781 |
| Tresiba Flextouch U-100Insulin Degludec | 57 | $50,244 |
| TymlosAbaloparatide | 17 | $49,776 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 249 | $48,892 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $46,455 |
| Humalog Kwikpen U-100Insulin Lispro | 102 | $38,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev | $6,013 | $776,245559 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,069 | $637,729412 claims |
| Boehringer IngelheimJardiance, Tradjenta | $7,240 | $202,771170 claims |
| AstraZenecaFarxiga | $556 | $69,79576 claims |
| Madrigal PharmaceuticalsRezdiffra | $6,952 | $52,78113 claims |
| Radius Health, Inc.Tymlos | $452 | $49,77617 claims |
| MerckJanuvia | $63 | $33,88235 claims |
| AbbVieSynthroid | $455 | $19,001241 claims |
| Mannkind CorporationAfrezza | $5,813 | $17,81619 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $178 | $9,560973 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Gilbert
- Shabeena ShaikGilbert$18K
- Muhammad SethiTucson$670K
- Kevin YuenPhoenix$404K
- Amir HarariScottsdale$361K
- Joan BaileyPhoenix$316K
- Kristina BlohmScottsdale$220K
- Karen HerbstTucson$200K
- Laura KnechtCave Creek$142K
- Andrea FerencziScottsdale$132K
- Nora BarsonyTucson$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.